STgen Bio announced Thursday its plans to expand its biopharmaceutical manufacturing plant in response to increased demand for high-titer biopharmaceuticals.
This expansion will include the addition of versatile, mid-sized facilities designed for multiproduct production, allowing the company to diversify its business portfolio and capture a larger share of global orders.
A significant investment of approximately 110 billion won ($77 million) will be allocated to expanding both drug substance and drug product production capabilities, as well as establishing essential supporting infrastructure. Upon completion of the project in the first quarter of 2028, production capacity is projected to increase from 9,000 liters to 14,000 liters.
To enhance production efficiency, the company will install two new bioreactors and one harvester. Crucially, the implementation of an isolator-type drug product filling line will guarantee a completely aseptic environment by minimizing manual intervention. This strategic investment is designed to meet the increasingly stringent standards required by global clients.
STgen Bio has already achieved regulatory approvals from 10 countries, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), demonstrating its commitment to quality and compliance.
“Leveraging our adherence to global regulatory standards and our proven track record in commercialization, we intend to concentrate on high-value-added products,” stated an STgen Bio official. “By enhancing our production capacities, we will ensure both stability and scalability, enabling us to respond flexibly to the needs of our global clientele.”
stlee0329
